The authors conducted a secondary analysis of the Expecting Study (NCT02125149) to examine glucoregulatory and inflammatory trajectories in pregnant women with obesity. The analysis used data from 263 sedentary participants with pre-pregnancy BMI ≥30 kg/m2 randomized to an exercise arm (EX, n=157) or standard-of-care (SoC, n=106). Fasting biomarkers were collected at three timepoints: mean 12.14±0.50, 24.19±0.68, and 36.03±0.58 weeks’ gestation. The investigators applied linear mixed-effects models to evaluate intervention and gestational effects focused on the 24–36 week window. An exploratory subgroup (n=18; EX=12, SoC=6) underwent repeated-measures continuous glucose monitoring (CGM) to characterize 24-h and temporal glycemia.
The trial registration and ethical approvals are documented in the source. The abstract does not present additional details on exercise prescription parameters in the body text beyond describing the intervention as moderate-intensity exercise; the source did not report further intervention dosing specifics in the abstract.
Data indicated progressive changes in glycemic physiology across pregnancy in this cohort. The study team reported increases in fasting insulin and C-peptide across gestation. Measures of insulin resistance and beta-cell function moved in expected directions: HOMA2-IR and HOMA2-%B rose with advancing gestation, while HOMA2-%S declined. All gestational trends for these glucoregulatory markers were reported with p<0.001 by the authors. Fasting glucose did not show an effect of the exercise intervention in the analyses summarized in the abstract.
These longitudinal shifts are consistent with physiologic insulin resistance of pregnancy. The investigators used mixed-effects modeling to separate intervention effects from gestational trajectories during the mid-to-late pregnancy interval described.
Inflammatory cytokine trajectories changed with gestation in the cohort. The authors observed increases in IL-6 and TNF-α over time. Conversely, CRP declined with advancing gestation according to the reported mixed-model results (all p<0.001 for gestational trends). These findings reflect dynamic immune and inflammatory shifts through pregnancy in women with obesity, as measured in fasting samples at the three protocol timepoints.
The abstract does not provide additional cytokine panel details beyond those specified, and it does not report cell-based immune measures or mechanistic assays in the text presented.
Investigators reported that the randomized moderate-intensity exercise intervention did not modify fasting glucoregulatory markers or inflammatory markers in mid-to-late gestation. Specifically, exercise did not affect fasting glucose or the inflammatory markers measured in fasting samples, as summarized in the abstract. The linear mixed-effects approach was used to test intervention and gestational effects between 24 and 36 weeks.
The abstract does not include additional subgroup analyses, per-protocol adherence metrics for the full cohort beyond the CGM subgroup, or differential effects by baseline characteristics in the text provided.
A small exploratory subsample wore continuous glucose monitors. CGM wear produced 12–15 days per trimester with >95% valid wear time as reported. Overall glycemia in the monitored participants remained in a normoglycemic range. Despite overall normoglycemia, the SoC group showed temporal changes by 36 weeks: declines in 24-h and nocturnal glucose and declines in time-in-range (TIR), with increased time-below-range (all p<0.022 reported by the authors).
The authors present CGM adherence as a strength for feasibility; however, the CGM sample was small and described as exploratory in the abstract. The source text did not provide expanded CGM protocol parameters or device model details in the abstract.
The study team explored associations linking CGM-derived metrics with inflammatory biomarkers. At 24 weeks, TIR was inversely associated with IL-6 (reported β=-0.23; 95%CI -0.43, -0.02; p=0.035). At 36 weeks, mean amplitude of glycemic excursion correlated positively with TNF-α (reported β=0.02; 95%CI 0.00, 0.04; p=0.033). These are presented as preliminary, exploratory associations in the abstract and were derived from the smaller CGM subgroup.
No causal inference is claimed in the source; the authors framed these as associations that could motivate further investigation.
The authors conclude that the randomized moderate-intensity exercise intervention did not change fasting glucoregulatory or inflammatory profiles in mid-to-late pregnancy within this cohort of women with obesity. They reported high CGM adherence in the exploratory subsample and identified preliminary, temporally distinct glycemic patterns and biomarker associations that the investigators suggest warrant further evaluation. The abstract specifies the CGM analyses were exploratory and limited by small sample size; it does not report expanded CGM protocol details or the full intervention dosing regimen in the abstract text. Future work, according to the authors, should expand CGM use in antepartum behavioral intervention trials to validate the preliminary associations and to better define temporal glycemic responses in pregnant populations with obesity.